Library of Slides and Posters

THE LOPSAQ STUDY: 48 THE LOPSAQ STUDY: 48-WEEK ANALYSIS OF A BOOSTED DOUBLE PROTEASE WEEK ANALYSIS OF A BOOSTED DOUBLE PROTEASE INHIBITOR (PI) REGIMEN CONTAINING LOPINAVIR/RITONAVIR (LPV/R) PL INHIBITOR (PI) REGIMEN CONTAINING LOPINAVIR/RITONAVIR (LPV/R) PLUS US SAQUINAVIR (SQV) WITHOUT ADDITIONAL ANTIRETROVIRAL THERAPY
S Staszewski and others. Abstract THPE0135.

The "95% adherence rule" may not apply tolopinavir/ritonavir (LPV/r) based HAART regimens
J Shuter and others. Abstract TUPE0110.

Lopinavir Concentrations Do Not Differ Between African-Americans and Caucasians Administered Once Daily HIV Therapy: The AAQD Study
D Wohl and others.

Economic and Clinical Impact of Using a Protease Inhibitor Regimen Containing ATV + RTV vs. Lopinavir/Ritonavir in Antiretroviral (ARV) Experienced Patients: Modeling the Lifetime Impacts of the 48-Week Results from BMS AI424-045
K Simpson and others.

Overview of Drug Interactions Between Brecanavir (BCV) and Other HIV Protease Inhibitors (PIs)
M Shelton and others. Abstract TUAB0105

Survey of Brecanavir (BCV) and Other Protease Inhibitor (PI) Susceptibility to HIV-1 Variants Containing PI Resistance- Associated Amino Acid Substitutions (RAS)
C Craig and others. Abstract THPE0023.

Kaletra BID vs LEXIVA BID, Both with EPIVIR and Abacavir QD, in ART-Naïve Patients: The KLEAN Study

Pharmacogenetic (PG) Investigation of Hypersensitivity to Abacavir
M Mosteller and others. Abstract WEPE0171.

The Impact of Patient, Disease, and Treatment-Related Factors on Quality of Life for HIV Patients on HAART
N Roskell and others. Abstract MOPE656.

Efficacy and safety results of 48 weeks of treatment with APTIVUS oral solution co-administered with low dose ritonavir (APTIVUS/r) in children and teenagers (Phase I/IIa study)
JC Salazar and others. Abstract WEAB0301.

A two-year randomized controlled clinical trial in antiretroviral-naïve subjects using lopinavir/ritonavir (LPV/r) monotherapy after initial induction treatment compared to an efavirenz (EFV) 3-drug regimen (Study M03-613)
W Cameron and others. Abstract THLB0201.

MONARK Trial (MONotherapy AntiRetroviral Kaletra): 48-Week Analysis of Lopinavir/Ritonavir (LPV/r) Monotherapy compared to LPV/r + Zidovudine/Lamivudine (AZT/3TC) in Antiretroviral-Naïve Patients
J Delfraissy and others. Abstract THLB0202.

Safety and Efficacy of Maraviroc (MVC), a Novel CCR5 Antagonist, When Used in Combination with Optimized Background Therapy (OBT) for the Treatment of Antiretroviral-Experienced Subjects Infected with Dual/Mixed-Tropic HIV-1: 24-Week Results of a Phase 2b Exploratory Trial
H Mayer and others. Abstract THLB0215.

ACTG 5211: phase II study of the safety and efficacy of vicriviroc in HIV-infected treatment-experienced subjects
R Gulick and others. Abstract THLB0217.

A structured treatment interruption (STI) strategy of 12 week cycles on and off ART is clinically inferior to continuous treatment in patients with low CD4 counts before ART: a randomisation within the DART trial
J Hakim and others. Abstract THLB0207.